Kestra Medical Technologies Ltd
Research Kestra Medical Technologies Ltd (KMTS) on Bullrun: market cap USD 1.57B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKMTS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Market capUSD 1.57B
- Financial periodQ2 2026
- RevenueUSD 28.64M
- Net income-USD 38.84M
- Free cash flow-USD 28.39M
- Gross margin54.8%
Valuation Snapshot
latest market cap is USD 1.57B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 59.82M | -USD 113.81M | -USD 100.54M | 40.5% | -5.13 | USD 237.60M | USD 41.10M | USD 205.41M |
| FY2024 | USD 27.81M | -USD 94.12M | -USD 84.46M | 1.3% | -5.07 | USD 8.25M | USD 42.54M | -USD 209.38M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.57B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.26B | n/a | n/a | n/a |
About Kestra Medical Technologies Ltd
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kestra Medical Technologies Ltd's market cap?
Kestra Medical Technologies Ltd's market capitalization is USD 1.57B.
What does Kestra Medical Technologies Ltd do?
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery.